抗真菌治疗策略及其对临床耐药发展的影响
本综述探讨侵袭性真菌病的治疗模式与减缓耐药策略。真菌通过靶酶突变、生物膜、外排泵过表达及药物渗透减少等机制耐药。先进诊断、治疗药物监测、新药(rezafungin、olorofim、fosmanogepix)、长效制剂、联合方案及免疫治疗有望改善疗效,需整合诊断、抗真菌药物管理(AFS)、精准医学与全球协作的「One Health」策略。
要点
- 真菌耐药机制多样,包括靶酶突变、生物膜、外排泵过表达和药物渗透减少。
- 治疗药物监测与先进诊断有助于及时靶向治疗并个体化方案,减少广谱药物依赖。
- 新药、长效制剂、联合方案及免疫治疗为管理耐药提供新途径。
核心结论
- 应对抗真菌耐药需整合稳健诊断、抗真菌药物管理、精准医学与全球协作的多层面「One Health」策略。
研究设计与样本
- 本文为综述,探讨抗真菌治疗模式并评估减缓耐药发展的方法。
主要发现
- 真菌病原体通过靶酶基因突变、生物膜形成、外排泵过表达和药物渗透减少等机制耐药。
- 先进诊断与治疗药物监测对实现及时靶向治疗和个体化方案至关重要,可减少对广谱药物的依赖。
- rezafungin、olorofim和fosmanogepix等新抗真菌药、长效与先进制剂及联合方案在管理耐药和改善结局方面显示前景。
- 免疫疗法与抗真菌疫苗的开发为增强宿主防御提供了新途径。
临床怎么用
- 临床应重视先进诊断与治疗药物监测,以支持及时、靶向和个体化的抗真菌治疗。
- 在管理耐药时,可考虑新抗真菌药、长效制剂、联合方案及免疫治疗等策略。
- 应推行前瞻性抗真菌药物管理实践,并与精准医学和全球协作相结合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Invasive fungal diseases, particularly among immunocompromised patients, represent a growing clinical challenge due to limited therapeutic options, diagnostic delays and escalating antifungal resistance. Fungal pathogens employ diverse resistance mechanisms, including genetic mutations of antifungal target enzymes, biofilm formation, efflux pump overexpression and reduced drug penetration, which compromise the efficacy of clinically available antifungal classes. This review explores antifungal treatment modalities and evaluates approaches to mitigate resistance development. Advanced diagnostics and therapeutic drug monitoring are pivotal for enabling timely, targeted therapies and personalizing treatment plans, thus minimizing reliance on broad-spectrum agents. New antifungal agents, such as rezafungin, olorofim and fosmanogepix, along with long-acting and advanced formulations plus combination regimens, show substantial promise for managing resistance and improving treatment outcomes. Additionally, the development of immunotherapies and antifungal vaccines offers new avenues for bolstering host defences against fungal pathogens. Addressing antifungal resistance demands a multifaceted 'One Health' approach that integrates robust diagnostics, antifungal stewardship (AFS), precision medicine and collaborative global efforts. By advancing drug formulations, enhancing diagnostic tools and implementing forward-thinking AFS practices, the healthcare community can better tackle the escalating burden of fungal infections and deliver improved patient outcomes.
引用
- Van Rhijn N, White PL. Antifungal treatment strategies and their impact on resistance development in clinical settings. J Antimicrob Chemother. 2025. PMID: 41092294. doi:10.1093/jac/dkaf382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。